Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Regulatory News (OKYO)

  • There is currently no data for OKYO

Exercise of Ferrum Option

2 Dec 2011 07:00

RNS Number : 2383T
Emerging Metals Limited
02 December 2011
Β 

ο»Ώ

For Immediate Release: 2 December 2011

Β 

Emerging Metals Limited

("EML" or the "Company")

Β 

Exercise of Ferrum Option

Β 

Further to the announcements made on 3 June 2011 and subsequently, the Company is pleased to announce that it has now exercised its option (the "Ferrum Option") to acquire all the issued and to be issued ordinary shares of Ferrum Resources Limited ("Ferrum" and "Ferrum Shares") not already owned by it, representing some 62.77 per cent. of Ferrum's issued ordinary share capital (the "Acquisition"). The Acquisition will in total involve the issue of 316,574,265 new ordinary shares of no par value in EML (the "Consideration Shares") with an aggregate value at the closing price on 1 December 2011 of 1.55 pence per EML share (the "Closing Price") of approximately Β£4.9 million. In addition, EML will grant warrants over a further 57,280,000 new EML ordinary shares ("Ordinary Shares"), each for a term of five years and with an exercise price per share of 4.88 pence and options over a further 5,012,000 new Ordinary Shares in respect of Ferrum employee options, exercisable for five years at a *formula price.

Β 

The Acquisition will constitute a reverse takeover under the AIM Rules and is therefore conditional, amongst other things, on the approval of EML's shareholders ("Shareholders") as well as on admission of the Consideration Shares to trading on AIM. A circular including details of a placing and constituting an admission document for the purposes of the AIM Rules will be posted to Shareholders in due course.

Β 

The directors believe the Acquisition will provide the Company with the opportunity to build a significant and diversified portfolio of interests in exploration assets that will accelerate the growth of the group and add Shareholder value.

Regent Mercantile Holdings Limited ("Regent Mercantile") is interested in 11,695,811 Ferrum Shares and holds an option to acquire a further 1,500,000 Ferrum Shares at an exercise price of 35 pence per Ferrum Share. Regent Mercantile is itself owned by a trust under which Stephen Dattels and members of his family may become beneficiaries. In accordance with the terms of the Ferrum Option, subject to completion of the Acquisition ("Completion"), Regent Mercantile will be issued 83,742,006 Consideration Shares (with a value at the Closing Price of approximately Β£1.3 million) and granted a new EML warrant to subscribe for 10,740,000 new Ordinary Shares at a price of 4.88 pence per EML Share for a period of five years from Admission.

Capital International (Nominees) Ltd ("Capital International") is interested in 3,285,714 Ferrum Shares. Capital International holds these shares for its client Galloway Limited, whose directors include Denham Eke and which is indirectly wholly owned by the trustee of a settlement under which James Mellon has a life interest. In accordance with the terms of the Ferrum Option, subject to Completion, Capital International will be issued 23,525,712 Consideration Shares (with a value at the Closing Price of approximately Β£365,000).

Since Messrs. Dattels, Mellon and Eke are all directors of the Company, the acquisition of Ferrum Shares from Regent Mercantile and Capital International and the grant of a new EML warrant to Regent Mercantile in exchange for the cancellation of its existing Ferrum options, which are being effected through the exercise of the Ferrum Option, are related party transactions for the purposes of the AIM Rules. Patrick Weller, who is for these purposes the Company's only independent director, considers, having consulted with Religare Capital Markets (UK) Limited, the Company's nominated adviser, that the terms of the Ferrum Option are fair and reasonable in so far as Shareholders are concerned.

Β 

Information on Ferrum

Β 

Ferrum is a private iron ore exploration and mining company incorporated in the British Virgin Islands on 18 January 2010. Since its incorporation, the company has focused on the acquisition of interests in early stage iron ore exploration projects in Africa. In the Cameroon, Ferrum holds a 63.53 per cent. equity interest in CMC Guernsey Limited, which through Compagnie Minière du Cameroun SA, a 95 per cent. owned subsidiary of CMC Guernsey Limited, holds six iron ore exploration permits in the Cameroon which cover an aggregate area of approximately 6,000 square kilometres in a region potentially prospective for iron ore. In Sierra Leone, Ferrum holds a 75 per cent. interest in five exploration licences (EL.05/11, EL.06/11, EL.07/11, EL.08/11 and EL.09/11), some of which are located adjacent to or on strike of known iron ore occurrences. Through a wholly owned subsidiary, Ferrum has applied for two exploration permits in Guinea although it is uncertain if, and when, these permits may be granted. From the date of incorporation to 31 March 2011, Ferrum made a loss of £1,205,000. Net assets as at 31 March 2011 amounted to £370,000.

* The formula price will be determined based on a price of US$0.305 per Ferrum Share converted to a price per EML Share at an exchange ratio of 7.16 and using the USD:GBP exchange rate on the date of grant.

Β 

For further information:

Β 

Emerging Metals Limited

Religare Capital Markets Limited

Evolution Securities Limited

GTH Communications

Denham Eke

Peter Trevelyan-Clark

Emily Staples

Β 

Jeremy Ellis

Matt Tyler

Toby Hall

Suzanne Johnson Walsh

+44 (0) 1624 639396

+44 (0) 20 7444 0800

+44 (0)20 7071 4300

+44 (0) 20 3103 3902

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
STRLIFFEFALFIIL
Date   Source Headline
19th May 20238:00 amRNSADS Program collapse
15th May 20237:00 amRNSChange of Record Time and Last Day of Dealings
11th May 202312:00 pmRNSWebull Corporate Communications Service Platform
11th May 20237:00 amRNSChange of Delisting Date to 22 May 2023
3rd May 20231:00 pmRNSResult of Meeting
3rd May 20237:00 amRNSPresentation on OK-101 at ASCRS
2nd May 20237:00 amRNSFirst-Patient First-Visit for Phase 2 Trial
25th Apr 20237:00 amRNSActivation of First Clinical Trial Site in the U.S
5th Apr 20237:00 amRNSNOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION
4th Apr 20237:00 amRNSNotice Of Intention To Delist From The LSE
30th Mar 20237:00 amRNSDirector Acquires Shares
29th Mar 20237:00 amRNSDirector acquires shares
24th Mar 20237:00 amRNSDirector/PDMR Shareholding
16th Mar 20237:01 amRNSListing of Trial on the ClinicalTrials.gov Website
16th Mar 20237:00 amRNSClosing of Global Private Placement
15th Mar 20237:01 amRNSDirector/PDMR Dealings
14th Mar 20237:00 amRNSIssue of Equity
13th Mar 20233:16 pmRNSCEO Interview
6th Mar 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSCustom Clearance of GMP Packaged OK-101 Drug
23rd Feb 20237:00 amRNSAppointment to Scientific Advisory Board
21st Feb 20237:00 amRNSCorporate Presentation
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20232:05 pmRNSSecond Price Monitoring Extn
20th Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 202311:05 amRNSSecond Price Monitoring Extn
20th Feb 202311:00 amRNSPrice Monitoring Extension
20th Feb 20239:05 amRNSSecond Price Monitoring Extn
20th Feb 20239:00 amRNSPrice Monitoring Extension
17th Feb 20234:40 pmRNSSecond Price Monitoring Extn
17th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSAllotment of Shares and Total Voting Rights
10th Jan 20234:40 pmRNSSecond Price Monitoring Extn
10th Jan 20234:35 pmRNSPrice Monitoring Extension
10th Jan 20232:05 pmRNSSecond Price Monitoring Extn
10th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 20231:15 pmRNSInterim Results - availability
30th Dec 20227:00 amRNSInterim Results for the Six Months Ending 30Sept22
22nd Dec 20227:00 amRNSU.S. FDA Clearance of IND Application for OK-101
21st Dec 20227:00 amRNSOKYO to Participate at Biotech Showcase
6th Dec 20227:00 amRNSOKYO files a registration statement with the SEC
1st Dec 20227:00 amRNSChange of Auditor
24th Nov 20227:00 amRNSDirector/PDMR Shareholding
21st Nov 20227:00 amRNSU.S. IND Filing on OK-101 for the Treatment of DED
20th Oct 20227:00 amRNSOKYO to participate at 2022 ThinkEquity Conference
8th Sep 20222:30 pmRNSOKYO interview on Bloomberg: RedChip Money Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.